Acute myeloid leukemia complicated with staghorn calculus

AML in children is a well-documented condition, but its association with urological complications remains underexplored. Prior research has shown that AML can lead to metabolic disturbances, including elevated uric acid and lactate dehydrogenase levels. However, the development of staghorn calculi in pediatric AML patients has not been previously reported. This gap motivated the documentation of this unique case. No prior work had resolved the link between AML treatment and subsequent renal stone formation. The knowledge of AML-related hyperleukocytosis is established, but its connection to urological outcomes is less understood. This uncertainty drove the need to investigate the interplay between leukemia and renal complications. The absence of pediatric cases with both AML and staghorn calculi highlights a need for further clinical observation. This paper aims to expand the understanding of rare urological sequelae in pediatric oncology.

The aim of this case report is to document a rare occurrence of staghorn calculi in a pediatric patient with AML. The specific problem addressed is the lack of prior pediatric cases linking AML with staghorn calculi. The motivation stems from the novelty of the clinical scenario and its potential to inform future care. The patient’s history of septicemia and chemotherapy raises questions about the role of these factors in stone formation. The study focuses on the diagnostic process and clinical management of a complex pediatric case. The goal is to highlight the importance of monitoring urological health in AML patients. The authors propose that this case may suggest a previously unrecognized association between AML treatment and renal complications. The findings may guide clinicians in identifying and managing similar cases in the future.

The study followed a clinical case approach, documenting the patient’s medical history and treatment timeline. Diagnostic imaging included plain abdominal X-ray and ultrasonography to identify the staghorn calculus. Laboratory tests measured serum uric acid and lactate dehydrogenase levels to assess metabolic status. The patient underwent chemotherapy for AML, followed by urological evaluation. Clinical records were reviewed to track the progression of the patient’s condition. The diagnosis of staghorn calculi was made 22 months after the start of chemotherapy. The authors used a descriptive method to present the case and its complications. The focus was on the unique combination of AML and staghorn calculi in a pediatric patient.

The patient was diagnosed with AML at age 11, presenting with hyperleukocytosis and elevated metabolic markers. Staghorn calculi were identified 22 months after chemotherapy initiation. Diagnostic imaging confirmed the presence of the calculus. The patient had a history of repeated septicemia episodes prior to stone formation. Serum uric acid and lactate dehydrogenase levels were significantly elevated at diagnosis. No prior pediatric cases of AML with staghorn calculi were found in the literature. The authors report this as the first known case in a child. The findings suggest a possible link between AML treatment and subsequent urological complications.

The authors conclude that this case represents a unique clinical scenario in pediatric oncology. The staghorn calculus developed following chemotherapy and repeated septicemia episodes. The findings may suggest a previously unreported association between AML treatment and renal stone formation. The case highlights the need for urological monitoring in AML patients. The authors propose that metabolic disturbances from AML may contribute to stone development. The report does not assign causality but emphasizes the importance of clinical observation. The novelty of the case lies in its pediatric context and the timing of stone formation. The authors suggest that this case may inform future studies on urological complications in AML patients.